These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9088592)

  • 1. Twenty-four hour plasma profile of sustained-release isosorbide mononitrate in healthy volunteers and in patients with chronic stable angina. Two open label trials.
    Baxter T; Eadie CJ
    Br J Clin Pharmacol; 1997 Mar; 43(3):333-5. PubMed ID: 9088592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained-release isosorbide mononitrate (50 mg): optimization of a once-daily dosage form for long-term treatment of angina pectoris.
    Bonn R
    Am J Cardiol; 1988 Mar; 61(9):12E-14E. PubMed ID: 3348135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isosorbide mononitrate 30% immediate-release 70% sustained-release formulation: a review. DUMQOL (DUtch Mononitrate Quality of Life) Study Group.
    Cleophas TJ; Niemeyer MG; Zwinderman AH; van der Wall EE
    Angiology; 2000 Aug; 51(8):631-8. PubMed ID: 10959515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal nitrate therapy with a once-daily sustained-release formulation of isosorbide mononitrate.
    Waller DG
    J Cardiovasc Pharmacol; 1999 Aug; 34 Suppl 2():S21-7; discussion S29-31. PubMed ID: 10499557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex-related differences in the pharmacokinetics of isosorbide-5-mononitrate (60 mg) after repeated oral administration of two different original prolonged release formulations.
    Vree TB; Dammers E; Valducci R
    Int J Clin Pharmacol Ther; 2004 Aug; 42(8):463-72. PubMed ID: 15366327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A sustained release formulation of isosorbide-5-mononitrate with a rapid onset of action.
    Arthur RM; Mehmel H
    Int J Clin Pract; 1999; 53(3):205-12. PubMed ID: 10665134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris.
    Chrysant SG; Glasser SP; Bittar N; Shahidi FE; Danisa K; Ibrahim R; Watts LE; Garutti RJ; Ferraresi R; Casareto R
    Am J Cardiol; 1993 Dec; 72(17):1249-56. PubMed ID: 8256699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-acting isosorbide mononitrate.
    Prakash A; Markham A
    Drugs; 1999 Jan; 57(1):93-9; discussion 100. PubMed ID: 9951954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Counterregulatory responses: sustained-release isosorbide-5-mononitrate versus transdermal nitroglycerin.
    Parker JD
    J Cardiovasc Pharmacol; 1996 Nov; 28(5):631-8. PubMed ID: 8945675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The plasma concentrations of isosorbide 5-mononitrate (5-ISMN) administered in an extended-release form to patients with acute myocardial infarction.
    McClennen W; Hornestam B; Jonsson UE; Held P
    Br J Clin Pharmacol; 1995 Jun; 39(6):704-8. PubMed ID: 7654494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single and multiple dose pharmacokinetic studies of oral sustained release and non-sustained release formulations of isosorbide-5-mononitrate in healthy volunteers.
    Zhang Q; Huang X; Ji P; Fu L; Yan B; Wei S
    Arzneimittelforschung; 1998 Jun; 48(6):641-5. PubMed ID: 9689420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Determination of isosorbide-5-mononitrate in plasma by GC-ECD and study on its pharmacokinetics in ten volunteers].
    Yang LL; Yuan YS; Zhao FL
    Yao Xue Xue Bao; 1997 Oct; 32(10):773-6. PubMed ID: 11596222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic profile of a new controlled-release isosorbide-5-mononitrate 60 mg scored tablet (Monoket Multitab).
    Stockis A; De Bruyn S; Deroubaix X; Jeanbaptiste B; Lebacq E; Nollevaux F; Poli G; Acerbi D
    Eur J Pharm Biopharm; 2002 Jan; 53(1):49-56. PubMed ID: 11777752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical pharmacokinetics of nitrates.
    Bogaert MG
    Cardiovasc Drugs Ther; 1994 Oct; 8(5):693-9. PubMed ID: 7873466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of isosorbide-5-mononitrate after oral administration of an extended-release mononitrate formulation versus a standard dinitrate formulation.
    Kosoglou T; Patrick JE; Cohen A; Radwanski E; Christopher D; Affrime MB
    Clin Ther; 1995; 17(2):241-51. PubMed ID: 7614524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of diet on the single-dose pharmacokinetics of isosorbide 5-mononitrate and sustained-release isosorbide dinitrate.
    Sata H; Inoue K; Nii T; Kuroda T
    Biol Pharm Bull; 1997 Oct; 20(10):1111-5. PubMed ID: 9353575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma profile and haemodynamic tolerance to isosorbide-5-mononitrate in controlled-release form.
    Jähnchen E
    Br J Clin Pharmacol; 1992; 34 Suppl 1(Suppl 1):15S-17S. PubMed ID: 1633073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized crossover trial of isosorbide mononitrate (Elantan 20) and slow-release glyceryl trinitrate in the treatment of angina pectoris.
    Brodie NH; O'Hara H; O'Hara J; Valle-Jones JC
    Pharmatherapeutica; 1985; 4(6):367-75. PubMed ID: 3936056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isosorbide 5-mononitrate: a review of a sustained-release formulation (Imdur) in stable angina pectoris.
    Gunasekara NS; Noble S
    Drugs; 1999 Feb; 57(2):261-77. PubMed ID: 10188765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of 8:00 a.m. and 2:00 p.m. doses of isosorbide-5-mononitrate during twice-daily therapy in stable angina pectoris.
    Thadani U; Bittar N
    Am J Cardiol; 1992 Aug; 70(3):286-92. PubMed ID: 1632390
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.